Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Rhea-AI Summary

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology firm specializing in immunotherapies for cancer and other severe diseases, will participate in the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on April 20, 2023, at 1:00 p.m. ET. This session will be a fireside chat featuring company management.

A live webcast will be available on Arcellx's website, and a replay will be accessible for 30 days post-event. Arcellx focuses on innovative cell therapies, including its lead candidate, CART-ddBCMA, targeting relapsed or refractory multiple myeloma, currently in a Phase 2 trial. The FDA has granted it several designations, including Fast Track and Orphan Drug.

REDWOOD CITY, Calif., April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 1:00 p.m. ET.

A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.

About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx's lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (rrMM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two clinical-stage programs: a Phase 1 study of ACLX-001 for rrMM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, initiated in the fourth quarter of 2022. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on Twitter (@arcellx) and LinkedIn.

Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx's expectations regarding the timing and outcomes of clinical trials for its product candidates and the potential impact of its product candidates and platforms on patients and cell therapy. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled "Item 1A. Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (SEC) on March 29, 2023, and other documents that Arcellx files from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investors:                                                                                                           
Myesha Lacy
ir@arcellx.com 
510-418-2412

Media:
Andrea Cohen Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163

View original content to download multimedia:https://www.prnewswire.com/news-releases/arcellx-to-participate-at-the-canaccord-genuity-2023-horizons-in-oncology-virtual-conference-301796533.html

SOURCE Arcellx, Inc.

FAQ

What is the date and time of Arcellx's participation in the Canaccord Genuity Oncology Conference?

Arcellx will participate on April 20, 2023, at 1:00 p.m. ET.

Where can I watch the Arcellx fireside chat?

The fireside chat will be available on Arcellx's website in the Investors section.

How long will the Arcellx webcast be available for replay?

The replay of the webcast will be available for 30 days after the event.

What is the lead product candidate of Arcellx?

Arcellx's lead candidate is CART-ddBCMA, developed for treating relapsed or refractory multiple myeloma.

What designations has the FDA granted to CART-ddBCMA?

CART-ddBCMA has received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations.